Health emergencies: let’s get prepared without leaving cancer patients behind
ESMO is advocating for secondary and tertiary care levels to be included into international agreements and WHO’s documents to respond to pandemics
Pregnancy after cancer- is it safe?
While increasing evidence from studies support pregnancy after cancer treatment, data gaps persist, particularly regarding the impact of novel therapies on fertility
Access to high-quality care for sarcomas is still unequal worldwide
Delays and poor patient journey are reported in resource-constrained countries, while awareness campaigns and healthcare service reorganisation have improved rare cancer management in more developed areas
Rare cancers in Asia – the value of registry data in low-resourced settings
While some challenges associated with rare cancers are similar in Europe and Asia, resources and differing epidemiology need to be considered when coming up with solutions
Ukraine: what help for refugees with breast cancer?
In neighbouring countries, oncologists are seeing a growing number of female refugees with breast cancer whose treatment may have started before they left Ukraine and urgently needs to be continued for good outcomes to be achieved.
Cancer care in war zones: what have we learnt?
In recent conflicts, good response to the health needs of refugees with cancer in receiving countries is consequence of an analysis of local cancer centres capacity and special measures to avoid fragmented care
COVID-19 vaccination is key to restoring early-phase anticancer drug development
Vaccination among cancer patients should not affect their participation in clinical trials and levels of acceptance of the vaccine are high
Progress is being made in treating sarcomas in adolescents and young people
Despite age-specific difficulties, increased understanding of sarcoma biology is leading the way to the development of new treatment strategies
Incorporating proteomics into sarcoma research: where do we stand?
Proteomic research on sarcomas is only in its infancy, but it offers potential in terms of improved biological understanding, identification of new treatment targets and generating biomarkers for patient selection and prognosis prediction
What level of evidence do we need for drug approval in rare cancers?
Achieving clarity in levels of clinical evidence required by regulatory bodies is still a major obstacle to expediting research in the field, says Prof. Paolo G. Casali from the Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, and the University of Milan, Italy